Quoin Pharmaceuticals Ltd. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Quoin Pharmaceuticals announced October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation for QRX003 for Peeling Skin Syndrome treatment, providing 10 years of market exclusivity in Europe upon approval. This is the eighth regulatory milestone for QRX003 across two indications (Peeling Skin Syndrome and Netherton Syndrome). The company stated it remains on track to initiate the first-ever formal clinical trial in Peeling Skin Syndrome before year-end 2026.
Why this rating
Orphan designation is material for a $5.4M biotech: regulatory de-risking, fee reductions, 10-year exclusivity post-approval. Meaningful milestone but approval remains years away; execution risk remains high.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-10.5% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.56 ▲ 10.95% | at our read · unknown $4.11 | +10 min · unknown $3.98 ▼ 3.28% | +30 min · unknown $3.98 ▼ 3.28% | +1 hr · unknown $4.02 ▼ 2.19% | +4 hrs · unknown $4.17 ▲ 1.46% |
The stock had already moved -9.87% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.